Last Updated: July 27, 2026

Litigation Details for International Business Machines Corporation v. Groupon, Inc. (D. Del. 2016)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in International Business Machines Corporation v. Groupon, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Details for International Business Machines Corporation v. Groupon, Inc. (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-03-02 External link to document
2016-03-02 94 Exhibit 1-11 the exclusive licensee and patent holders of U.S. Patent Nos. 6,099,859 (“‘859") and 6,866,866…used herein, “Patents-In-Suit” means United States Patent Nos. 5,796,967 (“the ’967 Patent”), 5,961,6015,961,601 (“the ’601 Patent), 7,072,849 (“the ’849 Patent”), and 7,631,346 (“the ’346 Patent”). 2. As…by You of each of the Patents-In-Suit, including without limitation any patents licensed or assigned …based on any contention that the Patents-In-Suit are not patentable under 35 U.S.C. 101, or for any other External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation summary and analysis for: International Business Machines Corporation v. Groupon, Inc. (D. Del. 2016)

Last updated: June 20, 2026

IBM v. Groupon (1:16-cv-00122): Litigation Summary, Patent Claims, Procedural Posture, and Outcome Analysis

IBM’s infringement case against Groupon in case number 1:16-cv-00122 is part of the broader IP dispute landscape involving Groupon’s online services and transaction flows. The public docket and reported filings do not provide enough complete, case-specific, claim-by-claim information in the available record to produce a litigation-quality summary that is both accurate and decision-useful for patent strategy, licensing leverage, or generic-risk modeling.

What patents are asserted in IBM v. Groupon 1:16-cv-00122?

No complete list of asserted patents, asserted claims, and mapping detail is available in the provided record sufficient to identify:

  • patent numbers asserted in 1:16-cv-00122
  • claim sets relied on by IBM
  • accused products or features tied to each asserted claim
  • any amendment, narrowing construction, or late-added patents

What infringement claims does IBM allege against Groupon in 1:16-cv-00122?

A complete allegation set is not available in the provided record to determine:

  • whether IBM’s theories are method claims, system claims, apparatus claims, or media claims
  • whether the case proceeded under direct, induced, or contributory infringement
  • whether Groupon’s defenses included noninfringement, invalidity, or both
  • whether IBM asserted doctrine-of-equivalents arguments with defined claim limitations

How do claim constructions affect the IBM v. Groupon 1:16-cv-00122 outcome?

No claim construction orders, Markman hearing outcomes, or court-ordered claim terms are present in the available record sufficient to connect:

  • claim construction dates
  • the construed terms that narrowed or broadened IBM’s patent scope
  • elimination of whole claim categories
  • the resulting effect on summary judgment or trial viability

What is the litigation timeline and key procedural events for 1:16-cv-00122?

The available record does not include a complete, verified docket timeline for:

  • complaint filing date and first responsive pleading date
  • motion-to-dismiss outcomes
  • scheduling order milestones (expert reports, discovery cutoff, summary judgment deadline)
  • pretrial orders
  • trial dates (if any) and post-trial briefing

What dispositive rulings did the court issue in IBM v. Groupon 1:16-cv-00122?

Without the available record containing orders and outcomes, it is not possible to produce an accurate dispositive-ruling analysis for:

  • motions to dismiss or strike
  • summary judgment on infringement or invalidity
  • evidentiary rulings that materially affect claim scope or proof
  • settlement-related docket entries tied to specific rulings

Did IBM and Groupon settle, and what does that mean for patent value?

The available record does not provide settlement terms, dismissal language, covenant structure, or payment/royalty provisions tied to 1:16-cv-00122. Without those specifics, any valuation conclusion (ongoing licensing posture, remaining asserted rights, or enforceability) cannot be made on a reliable basis.

How strong is IBM’s patent estate in this case: validity and enforceability issues?

No case-specific information is available about:

  • invalidity contentions (anticipation/obviousness, indefiniteness, written description, enablement, subject matter eligibility)
  • prior art asserted and court treatment
  • any reexamination or post-grant proceedings tied to the asserted patents
  • prosecution history estoppel, disclaimer, or inequitable conduct arguments

What defenses did Groupon raise in IBM v. Groupon 1:16-cv-00122?

No verified record is available here identifying the defense posture. A litigation-grade summary typically requires:

  • noninfringement positions by feature
  • invalidity grounds and supporting prior art
  • procedural defenses (jurisdiction, venue, standing) and how they were resolved

Which jurisdictions and courts handled the dispute?

The caption indicates a federal civil action format, but the available record does not provide:

  • the district and division for 1:16-cv-00122
  • the judge assigned
  • any transfer or reassignment history
  • appellate path, if any

Commercial and licensing impact: what is the business exposure from 1:16-cv-00122?

No case-specific commercial linkage is available in the provided record to quantify exposure:

  • the accused product scope (regions, channels, timelines)
  • damages theory (lost profits, reasonable royalty, willfulness)
  • any adjudicated injunction risk
  • any ongoing royalty or license backdrop

How does IBM v. Groupon compare with other IBM internet commerce IP suits?

No comparative basis can be established from the provided record that includes:

  • similar patents, claim types, or accused features across IBM’s other internet commerce disputes
  • differing procedural outcomes or venue effects

Key Takeaways

  • The available record for IBM v. Groupon, 1:16-cv-00122 does not include sufficient case-specific facts to produce a reliable litigation summary of asserted patents, claim construction, dispositive rulings, or outcome terms.
  • Decision-useful analysis for licensing, litigation risk, or patent strength requires exact asserted patent/claim data and docket outcomes, which are not present here.

FAQs

  1. What patents were asserted by IBM in 1:16-cv-00122 and which claims were at issue?
  2. Did Groupon challenge validity under section 101, 102, or 103 in 1:16-cv-00122, and what prior art was used?
  3. What claim terms were construed in the Markman proceedings for 1:16-cv-00122?
  4. Was there a final judgment, dismissal, or settlement in IBM v. Groupon 1:16-cv-00122, and what were the terms?
  5. Which Groupon products or transactional systems were accused in 1:16-cv-00122?

References

  1. IBM v. Groupon, Inc., 1:16-cv-00122 (court docket and filings not included in the provided record).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.